Filing Flows › Nektar Therapeutics (NKTR) › Q1 2026 › vs Q1 2025
Nektar Therapeutics (NKTR) Q1 2026 vs Q1 2025 (year over year)
Nektar Therapeutics's revenue rose $401K (+4%) from $10.5M in Q1 2025 to $10.9M in Q1 2026.
Nektar Therapeutics, Q1 2026: revenue $10.9M (+4% year over year), operating margin -359.6%, net loss $44.9M, operating cash flow −$44.3M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $10.9M | $10.5M | $401K | +4% |
| Net loss | $44.9M | $50.9M | −$6.0M | -12% |
| Costs & expenses | $55.8M | $61.3M | −$5.6M | -9% |
| Operating costs | $49.9M | $55.0M | −$5.1M | -9% |
| Interest & other, net | $5.8M | $6.3M | −$509K | -8% |
| Income tax | $64K | $52K | $12K | +23% |
| Research & development | $35.7M | $30.5M | $5.2M | +17% |
| General & admin | $13.4M | $24.3M | −$10.9M | -45% |
| Other operating costs | $796K | $169K | $627K | +371% |
| Operating cash sources | $47.8M | $53.4M | −$5.6M | -10% |
| Depreciation & amortization | $151K | $426K | −$275K | -65% |
| Share-based compensation | $3.4M | $3.9M | −$543K | -14% |
| Cash used in operations | $44.3M | $49.1M | −$4.8M | -10% |
| Net loss absorbed | $44.9M | $50.9M | −$6.0M | -12% |
| Working capital & other | $2.9M | $2.5M | $405K | +16% |
Questions
How much did Nektar Therapeutics's revenue grow year over year in Q1 2026?
Nektar Therapeutics's revenue rose $401K (+4%) from $10.5M in Q1 2025 to $10.9M in Q1 2026.